With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech
→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
